A recent scientific report has cast doubt on the extent to which Leqembi (lecanemab) and Kisunla (donanemab) meaningfully alter Alzheimer's progression, revealing a gap between revolutionary marketing and measured trial outcomes. Primary documents from the CLARITY AD trial published in the New England Journal of Medicine (2023) show lecanemab reduced clinical decline by 27% versus placebo over 18 months on the CDR-SB scale, while the TRAILBLAZER-ALZ 2 study for donanemab reported 35% slowing in intermediate tau subgroups. These translate to an estimated 4-7 month delay in noticeable worsening for early-stage patients, a far cry from reversal or cure.

Original coverage focused on the scientific questions but underplayed the policy and economic patterns this fits into. Pharma has repeatedly bet on the amyloid hypothesis, as seen in the accelerated FDA approval of aducanumab in 2021 (later withdrawn after controversy over conflicting trial data and marginal benefit). ICER's 2024 evidence report on anti-amyloid treatments concluded current pricing above $25,000 per year fails common cost-effectiveness thresholds, projecting billions in added Medicare spending for a therapy limited to patients with confirmed early pathology via expensive diagnostics.

Multiple perspectives emerge from primary sources: manufacturers emphasize amyloid plaque reduction as surrogate proof of disease modification and the first approved disease-modifying therapies, citing FDA decisions and patient advocacy calls for hope amid projected WHO tripling of dementia cases by 2050. Skeptical clinicians and independent reviewers highlight risks including ARIA brain swelling in 12-21% of trial participants, high discontinuation rates, and debate whether observed effects stem from amyloid clearance or other mechanisms, referencing NIH-backed studies questioning singular-target approaches. Policymakers face tensions between incentivizing innovation through accelerated pathways and ensuring fiscal sustainability for aging populations in both high-income systems and lower-resource settings where access remains negligible.

Mainstream reporting missed these connections to broader biotech hype cycles that drive stock volatility—Biogen and Eli Lilly shares have swung sharply on efficacy and safety updates—while diverting focus from combination therapies addressing tau, inflammation, and vascular factors. Synthesizing the NEJM trial reports, ICER assessment, and WHO dementia burden data shows the complicated reality: modest incremental gains amid overhyped promises risk inflating healthcare costs without proportional population-level impact, forcing governments to weigh coverage restrictions against equity concerns in global aging demographics.